M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$92bndisclosed · Pharma · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Oct 2026 | mAbxience | – | Fresenius | Acquisition | Completed | 1,946.9 | Biotech+1 | Lazard (buy-side) |
| Oct 2026 | HCXT-2001 (investigational oral IL-23R inhibitor) | PepStar Therapeutics | Gilead | Asset sale | Announced | – | Pharma+1 | Lazard |
| Oct 2026 | Orbus Therapeutics | – | US WorldMeds | Acquisition | Completed | – | Pharma+2 | Lazard |
| Sep 2026 | Royalty participation rights in U.S. net sales of tavapadon | Bain Capital | DRI Healthcare Trust | Asset sale | Announced | 316.0 | Specialty finance and leasing+2 | Cravath, Swaine & Moore (buy-side) |
| Sep 2026 | Stivarga (regorafenib) | Bayer AG | Grünenthal | Asset sale | Announced | 432.6 | Pharma+1 | Freshfields (buy-side) |
| Sep 2026 | portfolio of 20 mature medicines and three manufacturing sites | Sanofi | Cheplapharm | Asset sale | Announced | – | Pharma+1 | Freshfields (sell-side)Latham & Watkins (buy-side) |
| Aug 2026 | TYRVAYA (varenicline solution) nasal spray 0.03 mg | Viatris | Harrow | Asset sale | Announced | 30.0 | Pharma+1 | Cravath, Swaine & Moore (sell-side) |
| Aug 2026 | Lantheus Holdings | – | Curium US Holdings | Acquisition | Announced | 8,000.0 | Radiopharmaceuticals+1 | Morgan Stanley (sell-side)BofA Securities (sell-side)Solomon Partners (sell-side)Covington & Burling (sell-side)Ropes & Gray (sell-side)Jefferies (buy-side)J.P. Morgan (buy-side)PJT Partners (buy-side)Kirkland & Ellis (buy-side)Arnold & Porter (buy-side) |
| Aug 2026 | Supernus Pharmaceuticals | – | – | Merger | Announced | – | Pharma | Morgan Lewis (sell-side)Cantor Fitzgerald (sell-side)Wells Fargo Securities (sell-side)Saul Ewing (sell-side)Jefferies (buy-side)Piper Sandler (buy-side)Goodwin (buy-side)Citi (buy-side) |
| Aug 2026 | BWXT Medical business | BWX Technologies | Nordic Capital | Asset sale | Pending | 800.0 | Radiopharmaceuticals+2 | Solomon Partners (sell-side)Stikeman Elliott (sell-side)Kirkland & Ellis (buy-side)McCarthy Tétrault (buy-side) |
| Aug 2026 | global rights for MT-7117 (dersimelagon) | Tanabe Pharma | LEO Pharma | Asset sale | Completed | 435.0 | Pharma+2 | Evercore (sell-side)Latham & Watkins (buy-side) |
| Jul 2026 | Neurimmune's royalty interest in AstraZeneca's cliramitug | Neurimmune | Royalty Pharma | Asset sale | Announced | 250.0 | Pharma+1 | Goodwin (buy-side) |
| Jul 2026 | Avere Therapeutics | – | Hansoh Pharmaceutical Group Co. | Stake | Announced | – | Biotech+2 | Goodwin (buy-side) |
| Jul 2026 | newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business | Bayer | Apollo | Stake | Announced | 3,465.9 | Pharma | Latham & Watkins (buy-side)Paul, Weiss (buy-side) |
| Jul 2026 | iRenix Medical | – | Tarsus Pharmaceuticals | Acquisition | Announced | 75.0 | Ophthalmology+2 | Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side) |
| Jul 2026 | Crinetics Pharmaceuticals | – | Vertex Pharmaceuticals | Acquisition | Announced | 10,000.0 | Biotech+2 | Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Jul 2026 | Lannett | – | Aurobindo | Acquisition | Completed | 250.0 | Pharma+1 | Raymond JamesSullivan & Cromwell (buy-side) |
| Jun 2026 | Andone Pharmaceuticals | – | SteriMax | Acquisition | Completed | – | Pharma+2 | Bloom Burton & Co. (sell-side)Bourne Partners (buy-side) |
| Jun 2026 | Theravance Biopharma | – | Zymeworks | Acquisition | Pending | 929.0 | Pharma+1 | Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side) |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Completed | – | Biotech+2 | Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side) |
| Jun 2026 | US generic and specialty pharmaceutical product portfolio of Nordic Pharma | Nordic Pharma | J. Molner | Asset sale | Completed | – | Pharma | Raymond James |
| May 2026 | Altruix | WindRose Health Investors | Frazier Healthcare Partners | Acquisition | Completed | – | Behavioral Health+1 | Houlihan Lokey (sell-side)Cantor Fitzgerald (sell-side)Latham & Watkins (sell-side)Goodwin (buy-side) |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side) |
| May 2026 | Exclusive development and commercialisation rights to Idefirix in Europe and MENA | Hansa Biopharma AB | SERB Pharmaceuticals | Asset sale | Pending | 133.6 | Pharma+1 | Freshfields (buy-side)Mayer Brown (buy-side) |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) |
| May 2026 | Catalyst Pharmaceuticals | – | Angelini Pharma S.p.A. | Acquisition | Pending | 4,100.0 | Pharma+1 | J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side) |
| May 2026 | Esperion Therapeutics | – | ARCHIMED | Acquisition | Pending | 1,100.0 | Pharma+1 | Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side) |
| May 2026 | CVC and GBL-led Recordati acquisition consortium | – | CPP Investments | Stake | Announced | – | Pharma | Kirkland & Ellis (buy-side) |
| May 2026 | Recordati S.p.A. | – | CVC GBL | Acquisition | Announced | 12,516.9 | Pharma | Latham & Watkins (buy-side)Jefferies (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Shionogi-Apnimed Sleep Science | Apnimed | Shionogi & Co. | Acquisition | Announced | 100.0 | Pharma+1 | Goodwin (sell-side) |
| Apr 2026 | Emalex Biosciences | – | Teva Pharmaceuticals | Acquisition | Announced | 700.0 | Pharma+1 | Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side) |
| Apr 2026 | Organon & Co. | – | Sun Pharmaceutical Industries | Acquisition | Announced | 11,750.0 | Pharma | Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Cumberland FDA-approved commercial products and related assets | Cumberland Pharmaceuticals | Nuvo Pharmaceuticals (Ireland) DAC | Asset sale | Pending | 100.0 | Pharma | VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | US sales and distribution rights for seven Assertio branded products | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Announced | – | Pharma | Gibson Dunn (sell-side) |
| Apr 2026 | Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Completed | 35.0 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side) |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Announced | 35.0 | Pharma | Goodwin (buy-side) |
| Apr 2026 | Assertio Holdings | – | Zydus Worldwide DMCC | Acquisition | Announced | 166.4 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Cumberland U.S. branded businesses | Cumberland Pharmaceuticals | Apotex | Asset sale | Announced | – | Pharma | Kirkland & Ellis (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | AZSTARYS business | Corium Therapeutics Holdings | Collegium Pharmaceutical | Asset sale | Pending | 650.0 | Pharma | Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.